This protocol addresses morbid obesity in individuals who have undergone a structured lifestyle intervention program but have not reached the weight loss threshold that signals adequate response before advancing care.
The preceding line consisted of high-frequency counseling (≥16 sessions over 6 months) integrating nutrition changes, increased physical activity, and behavioral strategies — targeting a 500–750 kcal/day energy deficit with 200–300 min/week of physical activity. This approach did not achieve the goal of 5–7% weight loss, the threshold at which glycemia and intermediate cardiovascular risk factors are meaningfully improved.
The evidence-based next step adds pharmacotherapy to ongoing lifestyle modification. The preferred class of agents is receptor agonist-based therapy selected for weight-loss efficacy. Treatment is initiated conservatively and adjusted according to individual response. The complete agent selection, initiation approach, and titration guidance are in the full protocol.
The primary benchmark is >5% weight loss within the first 3 months of pharmacotherapy. Response is assessed at least monthly during the first 3 months and at least quarterly thereafter. Individuals who reach this early threshold are candidates for long-term continuation of treatment.
DOI: 10.2337/dc26-S008
Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes.
In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.
Obesity pharmacotherapy should be initiated at the lowest dose and the dose titration based on tolerability and response.
Unless clinical circumstances (such as poor tolerability) or other considerations (such as financial expense or individual preference) suggest otherwise, those who achieve sufficient early weight loss upon starting a chronic obesity pharmacotherapy (typically defined as >5% weight loss after 3 months of use) should continue the medication long-term.
Upon initiating medications for obesity, assess their effectiveness and safety at least monthly for the first 3 months and at least quarterly thereafter.
View source ↗